Figure 2From: Anti-tumor therapy with macroencapsulated endostatin producer cellsEndostatin delivered by engineered cells impaired tumor growth. (A), Solid lines: control group treated with LM(pSecTag) non-encapsulated cells (n = 6); Dashed lines: group treated with LM(pSecTag-end) non-encapsulated cells (n = 4); (B), Solid line: control group treated with LM(pSecTag) encapsulated cells injected into pre-implanted devices (n = 3); Dashed line: group treated with LM(pSecTag-end) injected into pre-implanted devices (n = 5); (C), Solid lines: control group treated with LM(pSecTag) non-encapsulated cells (n = 4); Dashed lines: group treated with LM(pSecTag-end) non-encapsulated cells (n = 4); (D), Solid line: control group treated with LM(pSecTag) encapsulated cells injected into devices which were then implanted into mice (n = 2); Dashed lines: group treated with LM(pSecTag-end) encapsulated cells using both protocols of implantation (n = 5); Inset D shows the same data as in D, Solid line: control group treated with LM(pSecTag) encapsulated cells injected into devices which were then implanted into mice (n = 2); Dotted line: group treated with LM(pSecTag-end) encapsulated cells injected into devices which were then implanted into mice (n = 3); Dashed line: group treated with 107 LM(pSecTag-end) encapsulated cells, injected into the pre-implanted devices (n = 2).Back to article page